Amagi Media Labs, a software-as-a-service (“SaaS”) company, is all set to launch its IPO (Initial Public Offering) on January 13, 2026, with anchor bidding scheduled on January 12, 2026. The company filed its red herring prospectus with SEBI on January 7, 2026.
Amagi Media Labs IPO Details
- Bidding Timeline: The IPO will remain open from January 13, 2026, to January 16, 2026
- Issue Size: The IPO is a book-build issue of ₹1,788.62 crores, consisting of a fresh issue of ₹816 crores and an Offer-for-Sale (OFS) of ₹972.62 crores.
- Price Band: The price band is set between ₹343 and ₹361 per share.
- Lot Size (for retail investors): 41 shares per lot
- Minimum Investment (for retail investors): ₹14,801 per lot based on the cut-off price
- Allotment & Listing: The basis of allotment will be finalised by January 19, 2026, and the tentative listing on BSE and NSE is scheduled for January 21, 2026.
- Book-running Lead Managers: Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Goldman Sachs (India) Securities Private Limited, IIFL Capital Services Limited (Formerly known as IIFL Securities Limited), and Avendus Capital Private Limited
- Registrar: MUFG Intime India Pvt Ltd
- Use of Proceeds: The net proceeds from the fresh issue will be used to fund
- Expenses towards technology and cloud infrastructure
- Inorganic growth through unidentified acquisitions
- General corporate purposes
Amagi Media Labs IPO GMP
As per media reports, the Grey Market Premium (GMP) of Amagi Media Labs is reported at ₹43 over the IPO price.
Amagi Media Labs Business Overview
Founded in 2008, Amagi Media Labs operates as a software-as-a-service (SaaS) provider that enables digital video delivery and monetisation for the global media and entertainment industry.
The company offers a cloud-native platform that allows media companies, content owners, and distributors to seamlessly upload, manage, and stream video content over the internet.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here